Highlands Oncology Group
Springdale, AR
Accepting patients
TRIlogy-5
A Phase 3 Randomized Study Comparing JNJ-79635322 Versus Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma After 1 to 3 Prior Lines of Therapy, Including an Anti-CD38 Antibody and Lenalidomide
- Trispecific Antibody
- T Cell Engager (TCE)
- BCMA
- GPRC5D
- Randomization
- Phase 3
Accepting patients
HLX15-SC
A Randomized, Double-blind, Parallel-controlled Phase I Study to Compare the Pharmacokinetic Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma
- Monoclonal Antibody
- CD38
- Closed Label (Masked)
- Randomization
- Phase 1